<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="functional receptor. Measures are currently undertaken worldwide to control the" exact="infection" post="to avoid disruption of the social and economic equilibrium,"/>
 <result pre="guarded optimistic view, we hope that the undertaken preventive and" exact="treatment" post="measures will at least contribute to contain viral diffusion,"/>
 <result pre="to identify the immune repertoire of CoV2-specific neutralizing antibodies. SARS-CoV2" exact="infection" post="prevention treatment immune system outbreak 1. Introduction The 2019"/>
 <result pre="the immune repertoire of CoV2-specific neutralizing antibodies. SARS-CoV2 infection prevention" exact="treatment" post="immune system outbreak 1. Introduction The 2019 novel coronavirus"/>
 <result pre="to salivary droplets, other routes of transmission of the viral" exact="infection" post="are possible [6]. Indeed, recent studies provide morphological and/or"/>
 <result pre="Indeed, recent studies provide morphological and/or proteomic evidence of SARS-CoV2" exact="infection" post="and host-viral protein interaction from human colon epithelial (Caco-2),"/>
 <result pre="COVID-19 infectious syndrome. From a pathogenetic point of view, the" exact="infection" post="begins when the virus passes the nasal and larynx"/>
 <result pre="and there are no specific antiviral treatments to defeat COVID-19" exact="infection" post="in humans and other animal species [18,19,20,21]. Thus, it"/>
 <result pre="review, we discuss emerging perspectives for the appropriate preventive and" exact="treatment" post="strategies to tackle COVID-19 infection. These include vaccine development"/>
 <result pre="We also highlight tools that may elucidate mechanisms governing viral" exact="infection" post="and clearance at the different stages of disease and"/>
 <result pre="reverse real-time PCR (rRT-PCR) are today the gold standard for" exact="screening" post="and diagnosis of COVID-19 infection in early stage, verifying"/>
 <result pre="PCR (rRT-PCR) are today the gold standard for screening and" exact="diagnosis" post="of COVID-19 infection in early stage, verifying its course,"/>
 <result pre="today the gold standard for screening and diagnosis of COVID-19" exact="infection" post="in early stage, verifying its course, and estimating the"/>
 <result pre="surveys in people suspected of current or previous SARS CoV2" exact="infection" post="through anti-viral IgG and IgM immunoglobulins testing. Accuracy of"/>
 <result pre="through anti-viral IgG and IgM immunoglobulins testing. Accuracy of antibodies" exact="detection" post="is assessed by enzyme-linked immunosorbent, chemiluminescence, and flow laminar"/>
 <result pre="longer-time immunity, although it is the last to rise after" exact="infection" post="since positivity occurs between 13â€&quot;21 days. Reported time to"/>
 <result pre="10 days following disease onset but declines soon after an" exact="infection" post="is cleared [25]. Combining serology with PCR results can"/>
 <result pre="with PCR results can enhance sensitivity and accuracy of early" exact="diagnosis" post="of CoV2 infection. Other abnormalities were detected in COVID-19"/>
 <result pre="severe complications of patients with COVID-19 as assessed by hemostasis" exact="testing" post="PT and D-dimer values [28,29]. 3. Treatment 3.1. Passive"/>
 <result pre="load, thus effectiveness of convalescent plasma (CP) immunotherapy for the" exact="treatment" post="of SARS-CoV and MERS-CoV [31]. In principle, this may"/>
 <result pre="not develop transfusion-related lung damage. Further, there was no antibody-dependent" exact="infection" post="enhancement that may occur when subneutralizing concentrations of antibodies"/>
 <result pre="difficulty of analyzing data due to confounding variables of other" exact="treatment" post="regimens, such as antivirals and anti-inflammatories administration [39]. Nevertheless,"/>
 <result pre="syndrome from 7 medical centers, CP therapy added to standard" exact="treatment" post="did not significantly improve timing to clinical amelioration within"/>
 <result pre="be experimented [46]. Remdesivir is an experimental drug for the" exact="treatment" post="of Ebola virus infection that was effective for the"/>
 <result pre="is an experimental drug for the treatment of Ebola virus" exact="infection" post="that was effective for the treatment of MERS and"/>
 <result pre="treatment of Ebola virus infection that was effective for the" exact="treatment" post="of MERS and SARS-CoV in animal models. Another possible"/>
 <result pre="replication and transcription. Transbodies have already being experimented for the" exact="treatment" post="of other infections, including those caused by influenza, hepatitis"/>
 <result pre="respect to CP transfusion [44]. 3.2. Therapeutics Management of COVID-19" exact="infection" post="aims first to ameliorate clinical manifestations and to provide"/>
 <result pre="Acute-Respiratory Disease Syndrome (ARDS) or extrapulmonary multiorgan failure, leading to" exact="infection" post="exacerbation or death. Therefore, immunomodulators and cytokine antagonists represent"/>
 <result pre="storm at the early stage to improve success rate of" exact="treatment" post="and reduce mortality rate. Tocilizumab is a recombinant humanized"/>
 <result pre="the membrane (mIL-6R) [57]. This drug is indicated for the" exact="treatment" post="of severe chronic inflammatory disorders, such as rheumatoid arthritis,"/>
 <result pre="have used steroids to control cytokine storm related to the" exact="infection" post="and occurrence of lung fibrosis. However, steroids have a"/>
 <result pre="Otherwise, virus replication and shedding and related symptoms of the" exact="infection" post="may exacerbate [59]. The utility of combined administration of"/>
 <result pre="(CQ) and hydroxychloroquine (HCQ) have been used for prevention and" exact="treatment" post="of malaria [63]. They have immunomodulatory, rather than suppressive,"/>
 <result pre="efficacy and acceptable safety of chloroquine or hydroxychloroquine in the" exact="treatment" post="of COVID-19 associated pneumonia [70]. Regarding potential side effects,"/>
 <result pre="can produce gastrointestinal side effects of vomiting and diarrhea. Long-term" exact="treatment" post="with CQ and HCQ can produce retinopathy and cardiomyopathy"/>
 <result pre="infection. This is a glycopeptide antibiotic, currently used in the" exact="treatment" post="of Gram-positive bacterial infection, especially in Staphylococcal infections. Already,"/>
 <result pre="from several concerns, which are not only control of the" exact="infection" post="in its spreading from its real geographical origin in"/>
 <result pre="animals that closely resemble the clinical disease caused by SARS-CoV2" exact="infection" post="in humans and its etiopathogenetic mechanisms [16]. These are"/>
 <result pre="skewed Th2 immune response are considered ideal for controlling SARS-CoV2" exact="infection" post="since the generation of a skewed Th2 T cell"/>
 <result pre="guarded optimistic view, we hope that the undertaken preventive and" exact="treatment" post="measures will at least contribute to contain diffusion, attenuate"/>
 <result pre="Although today there are no specific treatments for COVID-19, early" exact="diagnosis" post="and improved management of severe patients may reduce mortality."/>
 <result pre="anti-inflammatory drugs, such as tocilizumab, at early stage of the" exact="infection" post="for timely control of the disease and to avoid"/>
 <result pre="a near future to validate vaccination strategies in eradicating viral" exact="infection" post="from humans. In this regard, reverse vaccinology based on"/>
 <result pre="the pathway to novel diagnostic strategies [90,91]. Random peptide library" exact="screening" post="with CoV2 monoclonal antibodies may also lead to the"/>
 <result pre="[93], this approach may lead to elucidate mechanisms governing viral" exact="infection" post="and clearance at the different stages of disease and"/>
 <result pre="9.BouhaddouM.MemonD.MeyerB.WhiteK.M.RezeljV.V.MarreroM.C.PolaccoB.J.MelnykJ.E.UlfertsS.KaakeR.M.et al.The Global Phosphorylation Landscape of SARS-CoV-2 InfectionCell202010.1016/j.cell.2020.06.034 10.VargaZ.FlammerA.J.SteigerP.HabereckerM.AndermattR.ZinkernagelA.S.MehraM.R.SchuepbachR.A.RuschitzkaF.MochH.Endothelial cell" exact="infection" post="and endotheliitis in COVID-19Lancet20203951417141810.1016/S0140-6736(20)30937-532325026 11.PuellesV.G.LÃ¼tgehetmannM.LindenmeyerM.T.SperhakeJ.P.WongM.N.AllweissL.ChillaS.HeinemannA.WannerN.LiuS.et al.Multiorgan and Renal Tropism"/>
 <result pre="Calling for developing therapeutic and prophylactic strategiesEmerg. Microbes Infect.2020927527710.1080/22221751.2020.172344132005086 18.LuH.Drug" exact="treatment" post="options for the 2019-new coronavirus (2019-nCoV)Biosci. Trends202014697110.5582/bst.2020.0102031996494 19.SheahanT.P.SimsA.C.LeistS.R.SchÃ¤ferA.WonJ.BrownA.J.MontgomeryS.A.HoggA.BabusisD.ClarkeM.O.et al.Comparative"/>
 <result pre="Hospitalized with Severe Covid-19N. Engl. J. Med.20203821787179910.1056/NEJMoa200128232187464 57.BiggioggeroM.CrottiC.BeccioliniA.FavalliE.Tocilizumab in the" exact="treatment" post="of rheumatoid arthritis: An evidence-based review and patient selectionDrug"/>
 <result pre="evidence-based review and patient selectionDrug Des. Dev. Ther.201813577010.2147/DDDT.S150580 58.XuX.HanM.LiT.SunW.WangD.FuB.ZhouY.ZhengX.YangY.LiX.et al.Effective" exact="treatment" post="of severe COVID-19 patients with tocilizumabProc. Natl. Acad. Sci."/>
 <result pre="al.Triple combination of interferon beta-1b, lopinavirâ€&quot;ritonavir, and ribavirin in the" exact="treatment" post="of patients admitted to hospital with COVID-19: An open-label,"/>
 <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal modelCell Res.20122330030210.1038/cr.2012.16523208422 64.ZhouD.DaiS.-M.TongQ.COVID-19: A recommendation to"/>
 <result pre="A recommendation to examine the effect of hydroxychloroquine in preventing" exact="infection" post="and progressionJ. Antimicrob. Chemother.2020751667167010.1093/jac/dkaa11432196083 65.BorneB.E.V.D.DijkmansB.A.de RooijH.H.le CessieS.VerweijC.L.Chloroquine and hydroxychloroquine"/>
 <result pre="InteractionJ. Immunol.20151944089409310.4049/jimmunol.140279325821216 70.GaoJ.TianZ.YangX.Breakthrough: Chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studiesBiosci. Trends202014727310.5582/bst.2020.0104732074550 71.SchrezenmeierE.DornerT.Mechanisms"/>
 <result pre="for rheumatologyNat. Rev. Rheumatol.20201615516610.1038/s41584-020-0372-x32034323 72.BaronS.A.DevauxC.ColsonP.RaoultD.RolainJ.-M.Teicoplanin: An alternative drug for the" exact="treatment" post="of COVID-19?Int. J. Antimicrob. Agents20205510594410.1016/j.ijantimicag.2020.10594432179150 73.ZhouN.PanT.ZhangJ.LiQ.ZhangX.BaiC.HuangF.PengT.ZhangJ.LiuC.et al.Glycopeptide Antibiotics Potently"/>
 <result pre="the B- and T-cell response in a primary Zika virus" exact="infection" post="of a dengue-naÃ¯ve individual during the 2016 outbreak in"/>
 <result pre="host cell interaction. ijms-21-05145-t001_Table 1Table 1 Present Coronavirus (CoV) drug" exact="treatment" post="options. Treatment (Therapeutics Class) Target/Mechanism Reference Small molecules inhibitors"/>
 <result pre="cleavage/Inhibition of functional S1 and S2 subunits production [49] RBD-ACE2/BlockingS-protein-mediated" exact="infection" post="[49] RNA synthesis inhibitors (3TC, TDF) [18] Renin-angiotensin system"/>
</results>
